Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan:195:151-152.
doi: 10.1016/j.ahj.2017.09.004. Epub 2017 Sep 9.

Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project

Paul L Hess  1 , Kevin Kennedy  2 , Michael Cowherd  3 , Salim S Virani  4 , Frederick A Masoudi  3 , Ann Marie Navar  5 , Robert W Yeh  6 , P Michael Ho  7 , Thomas M Maddox  8
Affiliations

Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project

Paul L Hess et al. Am Heart J. 2018 Jan.
No abstract available

PubMed Disclaimer

Figures

Figure
Figure
Proportion of Patients With Atherosclerotic Cardiovascular Disease Potentially Eligible for PCSK9 Inhibitor Therapy According to LDL-C Treatment Thresholds and Statin Intensity.
See this image and copyright information in PMC

References

    1. [Accessed March 11, 2017]; https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm460082.htm.
    1. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376:1713–1722. - PubMed
    1. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jimenez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017;135:1851–1867. - PMC - PubMed
    1. Kazi DS, Penko J, Coxson PG, Moran AE, Ollendorf DA, Tice JA, Bibbins-Domingo K. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial. JAMA. 2017;318:748–750. - PMC - PubMed
    1. Virani SS, Akeroyd JM, Nambi V, Heidenreich PA, Morris PB, Nasir K, Michos ED, Bittner VA, Petersen LA, Ballantyne CM. Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs. Circulation. 2017;135:2572–2574. - PubMed

Publication types

MeSH terms